Join Josie

No telehealth services can legally or reliably offer compounded GLP-1s in the current FDA enforcement environment, as the agency has explicitly banned their marketing as substitutes for approved drugs and issued over 55 warning letters to companies (including Hims & Hers, SkinnyRx, and Join Josie) for misleading claims about these products[1][3][4]. Key details explaining why no service currently offers them: Factor Impact on Telehealth Services FDA Enforcement The FDA has resumed aggressive, batch-style enforcement targeting telehealth marketing of compounded GLP-1s, issuing 25 warning letters in June 2026 and 30 in March 2026[1][3] Legal Status Compounded GLP-1s are not FDA-approved and have not undergone rigorous safety, efficacy, or quality review[1] Company Actions Major providers like Hims & Hers have been referred to the Department of Justice and face restricted access to GLP-1 ingredients[9][4] FDA Stance The agency views compounded GLP-1s as "knockoff drugs" that pose significant safety risks and prohibits marketing them as equivalent to Ozempic, Wegovy, or Mounjaro[1][4] Recommendation for patients: Instead of seeking compounded GLP-1s, consult legitimate telehealth providers that offer FDA-approved GLP-1 medications (e.g., semaglutide for Ozempic/Wegovy, tirzepatide for Mounjaro) through verified pharmacy networks. Providers like Hims & Hers (despite enforcement actions) still offer FDA-approved alternatives, and established services such as Ro (Roman Health), Cure, and Plural provide access to approved GLP-1s via licensed pharmacies[4]. Compounded versions should only be used when a patient's medical needs cannot be met by FDA-approved drugs, per HHS guidelines[4].

Mentioned in position 3 of 6

Several telehealth services still appear to offer compounded GLP-1s, but the landscape changed sharply after the FDA’s March 2026 warning letters, and some companies have already shifted to branded products or stopped compounded offerings altogether.[4][2][3] Based on the sources you provided, the clearest names that were still associated with compounded GLP-1 access are: Hims & Hers — cited by CNBC as a company the FDA targeted and as still marketing a compounded GLP-1 offering at that time.[6] Amble Health — KFF Health News reported a patient receiving a GLP-1 prescription through Amble Health via online intake.[2] SkinnyRx — named by KFF as one of the telehealth companies receiving FDA warning letters.[2] Join Josie — named by KFF as another warned telehealth company.[2] Genesis Health International — also named by KFF among warned companies.[2] Lovely Meds — identified by STAT as one of the warned telehealth companies marketing compounded weight-loss drugs.[3] Hello Cake — identified by STAT as one of the warned telehealth companies.[3] MEDVi — identified by STAT as one of the warned telehealth companies.[3] A more important distinction: being named in a warning letter does not necessarily mean the company stopped offering compounded GLP-1s, only that the FDA believed its marketing was misleading or improper.[4][3] Some larger telehealth brands have reportedly moved away from compounded versions and toward FDA-approved branded medications like Wegovy or Zepbound instead.[2] If you want, I can also give you a current shortlist of telehealth companies most likely still offering compounded GLP-1s as of mid-2026, separated into: still likely active likely stopped too risky / under FDA scrutiny

Mentioned in position 4 of 8

Some telehealth services still offer compounded GLP-1s, but availability has narrowed and the FDA has specifically warned 30 telehealth companies against illegally marketing compounded GLP-1 products.[3] Compounded versions are not FDA-approved, and the FDA said the companies cited were making false or misleading claims about them.[3] From the search results, the telehealth brands/services explicitly mentioned as still involved with compounded GLP-1 access include: Amble Health — reported by KFF Health News as a telehealth company a patient used to obtain a GLP-1 after an online form.[1] Hims & Hers — named by the FDA among companies that received warning letters over compounded weight-loss drug claims.[1][3] SkinnyRx — also named in the FDA warning-letter sweep.[1][3] Join Josie — named in the FDA warning-letter sweep.[1][3] Genesis Health International — named in the FDA warning-letter sweep.[1][3] A practical takeaway is that some telehealth companies may still prescribe or facilitate compounded GLP-1s through compounding pharmacies, but the FDA crackdown means you should expect stricter sourcing, more warnings, and more companies exiting this market.[1][3][5] If you want, I can also give you a current shortlist of telehealth services that are still offering GLP-1s as of 2026, separated into: compounded GLP-1s brand-name Ozempic/Wegovy/Zepbound access most reputable options

Mentioned in position 4 of 5